PF-1355
Based on 4 publication(s) in Google Scholar
PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.80%
- CAS. Nr.: 1435467-38-1
- Formel: C14H15N3O4S
- Molecular Weight:321.35
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) PF-1355
More
Biologische Aktivität
In a dose-responsive fashion, PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1435467-38-1
-
Appearance Solid
-
Molecular Weight 321.35
-
Formel C14H15N3O4S
-
Color White to off-white
-
SMILES
O=C(N)CN(C(N1)=S)C(C2=CC(OC)=CC=C2OC)=CC1=O
-
Synonyms
PF-06281355
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
EBioMedicine
Neutrophil extracellular traps as a unique target in the treatment of chemotherapy-induced peripheral neuropathy. [Abstract]2023 Apr:90:104499. PMID: 36870200 -
Cancer Immunol Res
NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy. [Abstract]2022 Dec 2;10(12):1542-1558. PMID: 36255412 -
Rheumatology (Oxford)
Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]2025 Aug 13:keaf437. PMID: 40802538 -
bioRxiv
NETosis and Myeloperoxidase Promotes Inflammation and Cardiac Remodeling in Arrhythmogenic Cardiomyopathy. [Abstract]2026 Apr 17:2026.04.14.718596. PMID: 42039471
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (155.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
Plates are coated with the MPO capture antibody (1:200) overnight at 4°C, washed with PBS, and then nonspecific binding blocked with PBS/1% BSA. Plasma or peritoneal exudate samples are diluted 1:4 in PBS and 50 μL is added to triplicate wells for 1 hour at room temperature. Plates are washed three times with PBS containing 0.05% Tween, followed by PBS ishes. Assay buffer (50 μL containing 50 nM phosphate buffer, pH 7.4, containing 140 mM NaCl, 10 mM Na2NO2, 40 μM Amplex Red, and 10 μM H2O2) is added with kinetic reads and an excitation/emission wavelength of 530/580 nm on a fluorescence plate reader. Assay linearity is typically maintained for >300 seconds (R2 > 0.99) and Vmax represented by the change in relative fluorescence units divided by time to yield MPO activity. Active MPO is back-calculated using purified human MPO standard.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animals receive an intraperitoneal injection of 4% thioglycollate broth in phosphate-buffered saline (PBS) for neutrophil recruitmen. Twenty hours later, PF-1355 or vehicle (1% hydroxypropyl methylcellulose, 0.5% 2-amino-2-hydroxymethyl-propane-1,3-diol, 0.5% hypromellose acetate succinate, pH 9.5) is administered p.o., followed by intraperitoneal administration of opsonized zymosan or saline. After 3 hours, the mice are euthanized and receive intraperitoneal injection of 2 mL cold PBS. Blood is collected and animals are shaken vigorously before the collection of peritoneal lavage.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1119 mL | 15.5594 mL | 31.1187 mL | 77.7968 mL |
| 5 mM | 0.6224 mL | 3.1119 mL | 6.2237 mL | 15.5594 mL | |
| 10 mM | 0.3112 mL | 1.5559 mL | 3.1119 mL | 7.7797 mL | |
| 15 mM | 0.2075 mL | 1.0373 mL | 2.0746 mL | 5.1865 mL | |
| 20 mM | 0.1556 mL | 0.7780 mL | 1.5559 mL | 3.8898 mL | |
| 25 mM | 0.1245 mL | 0.6224 mL | 1.2447 mL | 3.1119 mL | |
| 30 mM | 0.1037 mL | 0.5186 mL | 1.0373 mL | 2.5932 mL | |
| 40 mM | 0.0778 mL | 0.3890 mL | 0.7780 mL | 1.9449 mL | |
| 50 mM | 0.0622 mL | 0.3112 mL | 0.6224 mL | 1.5559 mL | |
| 60 mM | 0.0519 mL | 0.2593 mL | 0.5186 mL | 1.2966 mL | |
| 80 mM | 0.0389 mL | 0.1945 mL | 0.3890 mL | 0.9725 mL | |
| 100 mM | 0.0311 mL | 0.1556 mL | 0.3112 mL | 0.7780 mL |
PF-1355 Related Classifications
HY-100873 Related Classifications
Powered by Bioz